Dr. Tithi Biswas
Claim this profileCase Western Reserve University
Studies Lung Cancer
Studies Cancer
6 reported clinical trials
21 drugs studied
Area of expertise
1Lung Cancer
Stage IV
Stage II
Stage I
2Cancer
Stage III
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Tithi Biswas is currently running
TRC102 + Chemotherapy/Radiation
for Lung Cancer
This phase II trial tests whether TRC102 (methoxyamine hydrochloride) in combination usual care treatment comprised of pemetrexed, cisplatin or carboplatin, and radiation therapy followed by durvalumab works better than the usual care treatment alone to shrink tumors in patients with stage III non-squamous non-small cell lung cancer (NSCLC). TRC102 is in a class of drugs called antineoplastic agents. It blocks the ability of a cell to repair damage to its DNA and may kill cancer cells. It may also help some anticancer drugs work better. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make DNA and may kill cancer cells. Chemotherapy drugs, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy sources to kill tumor cells and shrink tumors. Giving TRC102 in combination with usual care treatment may be more effective than usual care treatment alone in stabilizing and lengthening survival time in patients with stage III non-squamous NSCLC.
Recruiting1 award Phase 224 criteria
MRI Monitoring vs. Preventive Brain Radiation
for Small Cell Lung Cancer
This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer. MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving PCI and prolong patients' lifespan. Monitoring with MRI scans alone (delaying radiation until the actual spread of the cancer) may be at least as good as the combination of PCI with MRI scans.
Recruiting2 awards Phase 322 criteria
More about Tithi Biswas
Clinical Trial Related5 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Tithi Biswas has experience with
- Cisplatin
- Atezolizumab
- TRC102
- Pemetrexed
- Durvalumab
- Methoxyamine
Breakdown of trials Tithi Biswas has run
Lung Cancer
Cancer
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Tithi Biswas specialize in?
Tithi Biswas focuses on Lung Cancer and Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage II.
Is Tithi Biswas currently recruiting for clinical trials?
Yes, Tithi Biswas is currently recruiting for 2 clinical trials in Cleveland Ohio. If you're interested in participating, you should apply.
Are there any treatments that Tithi Biswas has studied deeply?
Yes, Tithi Biswas has studied treatments such as Cisplatin, Atezolizumab, TRC102.
What is the best way to schedule an appointment with Tithi Biswas?
Apply for one of the trials that Tithi Biswas is conducting.
What is the office address of Tithi Biswas?
The office of Tithi Biswas is located at: Case Western Reserve University, Cleveland, Ohio 44106 United States. This is the address for their practice at the Case Western Reserve University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.